Declines in proton therapy sales and dosimetry revenues contributed to a revenue dip for radiopharmaceutical provider Ion Beam Applications (IBA), but profits still increased.
For the first half of 2013 (end-30 June), the company recorded 97.4 million euros in sales and services, down 8.2% from the 106.1 million euros reported in the first half of 2012. While IBA had 13.7% sales growth in its accelerator business, a low conversion rate of proton therapy order bookings due to customer production planning led to a 14.4% drop in proton therapy sales in the first half of 2013, according to the firm.
IBA also pointed to uncertainties in the U.S. medical device market and the currency exchange rate as the key factor in a 6.5% decline in dosimetry revenues, obscuring good performance in emerging markets.
Thanks to its efficiency programs, however, IBA posted net profit of 4.13 million euros for the first half of 2013. The firm had a net loss of 1.4 million euros in the first half of 2012.
